Kasper Siegfried

Learn More
In a double-blind randomized group design, nomifensine (100 mg single daily dose) was compared to placebo in 100 geriatric inpatients (average age = 75 years). Patients in each group were categorized as depressed (Feighner criteria for primary depressive disorder and Hamilton Depression Rating Scale scores greater than or equal to 18) or non-depressed (no(More)
The effects of a single oral dose of the acetylcholinesterase inhibitor velnacrine maleate on word and object recognition memory and regional uptake of99mTc-exametazime were examined in patients with Alzheimer's disease. Word recognition memory was marginally improved 2 h after 75 mg velnacrine. With the same dose of velnacrine a relative increase in(More)
A review of pharmacodynamic studies of nomifensine in healthy subjects indicates that nomifensine caused neither negative nor positive (euphoric) mood alterations and led to no impairments in various tests of performance and to some improvement in vigilance, attention, and psychomotor performance. Nomifensine was shown to alter the waking EEG in a manner(More)
s | 73 Abstract Background: Increasing evidence show that disruption of connectivity has been implicated as a central abnormality in schizophrenia, and the alterations in white matter (WM) may be the core basis for this disconnection. Diffusion tensor imaging (DTI) has shown WM abnormalities in first episode schizophrenia. However, few studies have examined(More)
Scopolamine produces a satisfactory model of the attentional and secondary memory deficits seen in Alzheimer's disease (AD) that can be used to screen compounds for potential therapeutic usefulness. Physostigmine, which is known to enhance memory in AD, produced marked and widespread antagonism of the scopolamine-induced impairments, indicating the(More)
  • 1